Aliases & Classifications for Syncope

MalaCards integrated aliases for Syncope:

Name: Syncope 53 29 6

Summaries for Syncope

NINDS : 53 Syncope is a medical term used to describe a temporary loss of consciousness due to the sudden decline of blood flow to the brain. Syncope is commonly called fainting or “passing out.” If an individual is about to faint, he or she will feel dizzy, lightheaded, or nauseous and their field of vision may “white out” or “black out.”  The skin may be cold and clammy.  The person drops to the floor as he or she loses consciousness.  After fainting, an individual may be unconscious for a minute or two, but will revive and slowly return to normal.  Syncope can occur in otherwise healthy people and affects all age groups, but occurs more often in the elderly.  There are several types of syncope.  Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing.  Carotid sinus syncope happens because of constriction of the carotid artery in the neck and can occur after turning the head, while shaving, or when wearing a tight collar.  Situational syncope happens during urination, defecation, coughing, or as a result of gastrointestinal stimulation.  Syncope can also be a symptom of heart disease or abnormalities that create an uneven heart rate or rhythm that temporarily affect blood volume and its distribution in the body.  Syncope isn’t normally a primary sign of a neurological disorder, but it may indicate an increased risk for neurologic disorders such as Parkinson’s disease, postural orthostatic tachycardia syndrome (POTS), diabetic neuropathy, and other types of neuropathy.  Certain classes of drugs are associated with an increased risk of syncope, including diuretics, calcium antagonists, ACE inhibitors, nitrates, antipsychotics, antihistamines, levodopa, narcotics, and alcohol.

MalaCards based summary : Syncope is related to familial short qt syndrome and long qt syndrome 10. An important gene associated with Syncope is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are cGMP-PKG signaling pathway and Cardiac conduction. The drugs Diclofenac and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and brain, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 74 Syncope, also known as fainting, is a loss of consciousness and muscle strength characterized by a fast... more...

Related Diseases for Syncope

Diseases related to Syncope via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Related Disease Score Top Affiliating Genes
1 familial short qt syndrome 10.3 KCNQ1 KCNH2
2 long qt syndrome 10 10.3 SCN5A KCNQ1
3 arrhythmogenic right ventricular dysplasia, familial, 12 10.1 RYR2 KCNH2
4 familial long qt syndrome 10.1 SCN5A KCNQ1 KCNH2
5 long qt syndrome 14 10.1 SCN5A KCNQ1 KCNH2
6 long qt syndrome 13 10.1 SCN5A KCNQ1 KCNH2
7 long qt syndrome 12 10.1 SCN5A KCNQ1 KCNH2
8 right bundle branch block 10.1 SCN5A KCNH2
9 long qt syndrome 6 10.1 SCN5A KCNQ1 KCNH2
10 epileptic encephalopathy, early infantile, 14 10.1 SCN5A KCNQ1 KCNH2
11 progressive familial heart block, type ia 10.1 TTN SCN5A
12 long qt syndrome 5 10.1 SCN5A KCNQ1 KCNH2
13 brugada syndrome 4 10.1 SCN5A KCNQ1 KCNH2
14 long qt syndrome 9 10.1 SCN5A KCNQ1 KCNH2
15 cardiomyopathy, dilated, 1b 10.0 TTN SCN5A
16 jervell and lange-nielsen syndrome 1 10.0 SCN5A KCNQ1 KCNH2
17 dopamine beta-hydroxylase deficiency 10.0 SLC6A2 DBH
18 familial isolated arrhythmogenic ventricular dysplasia, left dominant form 10.0 TTN RYR2
19 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 10.0 TTN RYR2
20 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 10.0 TTN RYR2
21 cardiomyopathy, dilated, 1dd 10.0 TTN RYR2
22 arrhythmogenic right ventricular dysplasia, familial, 1 10.0 TTN RYR2
23 atrial standstill 10.0 SCN5A NPPA
24 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.0 SCN5A KCNQ1 KCNH2
25 ebstein anomaly 10.0 TNNT2 SCN5A
26 brugada syndrome 1 10.0 SCN5A RYR2 KCNH2
27 neuromuscular junction disease 9.9 SCN5A RYR2 KCNH2
28 oppositional defiant disorder 9.9 SLC6A2 DBH
29 supravalvular aortic stenosis 9.9 SCN5A KCNH2
30 malignant hyperthermia 9.9 SCN5A RYR2 KCNH2
31 third-degree atrioventricular block 9.9 TTN SCN5A KCNH2
32 congenital structural myopathy 9.9 TTN RYR2
33 cardiomyopathy, familial hypertrophic, 4 9.9 TTN TNNT2
34 peripartum cardiomyopathy 9.9 TTN SCN5A
35 left bundle branch hemiblock 9.8 TNNT2 SCN5A RYR2
36 isolated elevated serum creatine phosphokinase levels 9.8 TTN SCN5A RYR2
37 cardiac conduction defect 9.8 SCN5A RYR2 KCNQ1 KCNH2
38 sinoatrial node disease 9.8 SCN5A RYR2 KCNQ1 KCNH2
39 long qt syndrome 3 9.8 SCN5A RYR2 KCNQ1 KCNH2
40 cardiac arrhythmia 9.8 SCN5A RYR2 KCNQ1 KCNH2
41 cardiac arrhythmia, ankyrin-b-related 9.8 SCN5A RYR2 KCNQ1 KCNH2
42 andersen cardiodysrhythmic periodic paralysis 9.8 SCN5A RYR2 KCNQ1 KCNH2
43 timothy syndrome 9.8 SCN5A RYR2 KCNQ1 KCNH2
44 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 9.8 SCN5A RYR2 KCNQ1 KCNH2
45 myasthenic syndrome, congenital, 5 9.7 SCN5A RYR2 KCNQ1 KCNH2
46 long qt syndrome 2 9.7 SCN5A RYR2 KCNQ1 KCNH2
47 short qt syndrome 9.7 SCN5A RYR2 KCNQ1 KCNH2
48 progressive familial heart block 9.7 TNNT2 SCN5A KCNQ1 KCNH2
49 sudden infant death syndrome 9.7 SCN5A RYR2 KCNQ1 KCNH2
50 cardiomyopathy, familial hypertrophic, 1 9.7 TTN TNNT2 KCNQ1

Graphical network of the top 20 diseases related to Syncope:



Diseases related to Syncope

Symptoms & Phenotypes for Syncope

MGI Mouse Phenotypes related to Syncope:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 DBH KCNH2 KCNQ1 NPPA RYR2 SCN5A
2 growth/size/body region MP:0005378 9.76 DBH KCNH2 KCNQ1 RYR2 SCN5A SLC6A2
3 muscle MP:0005369 9.5 KCNH2 KCNQ1 NPPA RYR2 SCN5A TNNT2
4 normal MP:0002873 9.1 DBH KCNQ1 RYR2 SCN5A TNNT2 TTN

Drugs & Therapeutics for Syncope

Drugs for Syncope (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 274)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
4
Propranolol Approved, Investigational Phase 4 525-66-6 4946
5
Amlodipine Approved Phase 4 88150-42-9 2162
6
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
7
Losartan Approved Phase 4 114798-26-4 3961
8
Bisoprolol Approved Phase 4 66722-44-9 2405
9
Interferon beta-1b Approved Phase 4 145155-23-3
10
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
11
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
12
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
13
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
14
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
15
Cefpirome Approved Phase 4 84957-29-9 5479539
16
Ticagrelor Approved Phase 4 274693-27-5 9871419
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
19
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
20
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
21
Ramipril Approved Phase 4 87333-19-5 5362129
22
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
23
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
24
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
25
Silodosin Approved Phase 4 160970-54-7
26
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
27
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
28
Procainamide Approved Phase 4 51-06-9 4913
29 Adrenergic alpha-Agonists Phase 4
30 Adrenergic Agonists Phase 4
31 Antiparkinson Agents Phase 4
32 Dopamine Agents Phase 4
33 Anti-Inflammatory Agents Phase 4
34 Protective Agents Phase 4
35 Hormones Phase 4
36 Analgesics Phase 4
37 Calcium, Dietary Phase 4
38 calcium channel blockers Phase 4
39 Analgesics, Non-Narcotic Phase 4
40 Cyclooxygenase Inhibitors Phase 4
41 Antirheumatic Agents Phase 4
42 Anti-Inflammatory Agents, Non-Steroidal Phase 4
43 Interferon-beta Phase 4
44 (T,G)-A-L Phase 4
45 Fingolimod Hydrochloride Phase 4
46 interferons Phase 4
47
Glatiramer Acetate Phase 4 147245-92-9 3081884
48 Norgestimate, ethinyl estradiol drug combination Phase 4
49 calcium heparin Phase 4
50 Antioxidants Phase 4

Interventional clinical trials:

(show top 50) (show all 391)
# Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope Unknown status NCT01621464 Phase 4
2 Effect of Pre-medication in Pain Measures on Office Hysteroscopy - Randomized Clinical Trial Unknown status NCT03506763 Phase 4 Placebo Oral + Placebo Oral;Diclofenac oral + Placebo Oral;Diclofenac oral + scopolamina oral
3 Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
4 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Pacemaker Therapy for Patients With Asystolic Neurally-mediated Syncope Completed NCT00359203 Phase 4
5 A Randomized Clinical Trial of Fludrocortisone for Vasovagal Syncope: The Second Prevention of Syncope Trial (POST II) Completed NCT00118482 Phase 4 fludrocortisone acetate
6 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
7 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
8 Propranolol for Syncope With Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
9 The COMPAriSon of Systolic Blood Pressure Variability and Central Blood Pressure of Calcium Channel Blocker (Amlodipine) in Comparison With Angiotensin Receptor Blocker (Losartan) in Patients With Essential Hypertension Completed NCT01964079 Phase 4 Amlodipine;Losartan
10 Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM) Completed NCT01074307 Phase 4 Low Dose Bisoprolol;High Dose Bisoprolol
11 A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS) Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
12 Post Marketing Surveillance Study for LDL Apheresis Using H.E.L.P. Therapy Completed NCT00916643 Phase 4
13 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
14 Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease Completed NCT02383771 Phase 4 Ticagrelor;Aspirin + Ticagrelor;Control;Aspirin + Ticagrelor
15 An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose Completed NCT00344994 Phase 4 pramipexole
16 Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
17 Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease Completed NCT02525081 Phase 4 Ramipril (ACE-inhibitor);placebo
18 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
19 Effect of Pacemaker With Closed Loop Sensor on Quality of Life and Recurrence of Syncope in Patients With Neuromodulated Syncope Refractory to Medical Treatment: Randomized Double-blind Clinical Trial Recruiting NCT03876652 Phase 4
20 Randomized Evaluation of Beta Blocker and Angiotensin Converting Enzyme Inhibitor (ACEI) /Angiotensin Receptor Blocker (ARB) Treatment in MINOCA Patients. Recruiting NCT03686696 Phase 4 Beta blocker;ACEI;ARB
21 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4) Active, not recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
22 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
23 Comparison of Intravenous Amiodarone Versus Intravenous Procainamide for the Acute Treatment of Regular and Haemodynamically Well Tolerated Wide QRS Tachycardia (Probably of Ventricular Origen). The PROCAMIO Multicenter Study Terminated NCT00383799 Phase 4 iv Amiodarone;iv Procainamide
24 Comparison of Silodosin vs. Tamsulosin on Spontaneous Passage of Acutely Obstructing Ureteral Calculi in Medical Expulsive Therapy Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
25 Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo Unknown status NCT02071459 Phase 2, Phase 3 L-Threo DOPS;placebo
26 Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome Unknown status NCT02823080 Phase 2, Phase 3 Cetrorelix
27 Randomized, Double-Blinded, Oseltamivir-and-Placebo-Controlled Clinical Study About Lingdancao Granules in the Treatment of Seasonal Influenza Unknown status NCT02662426 Phase 3 Lingdancao granules;analogous oseltamivir phosphate capsule;Oseltamivir phosphate capsule;analogous Lingdancao granules
28 Randomized Controlled Trial on Discontinuation of Vasoactive Drugs in Patients With Hypotensive Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
29 Comparison of Ivabradine and Beta-blockers Administration in the Treatment of Inappropriate Sinus Tachycardia Completed NCT01657136 Phase 3 Ivabradine;Beta blocker
30 CSP #563 - Prazosin and Combat Trauma PTSD (PACT) Completed NCT00532493 Phase 3 prazosin
31 Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed NCT00000464 Phase 3 amiodarone;imipramine;mexiletine;procainamide;propafenone;quinidine;sotalol
32 Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14) Completed NCT01863186 Phase 3 Lofexidine HCl;Placebo;Open Label Lofexidine HCL
33 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00782340 Phase 3 Placebo;Droxidopa
34 A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
35 Antiarrhythmics Versus Implantable Defibrillators (AVID) Completed NCT00000531 Phase 3 amiodarone amiodarone;sotalol
36 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00633880 Phase 3 Placebo;Droxidopa
37 An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension Completed NCT00738062 Phase 3 Droxidopa;Placebo
38 Comprehensive Approach to Lower Measured Blood Pressure (CALM-BP) - Results From a Randomized Controlled Trial Completed NCT00409149 Phase 3
39 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
40 Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
41 Liposomal Bupivacaine To Control Post-Operative Pain Following Buccal Mucosal Graft Harvesting Active, not recruiting NCT03720223 Phase 3 Liposomal Bupivacaine
42 A Double Blind Randomized Controlled Crossover Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe Postural Orthostatic Tachycardia Syndrome Not yet recruiting NCT03365414 Phase 3 Normal Saline 0.9% Infusion Solution Bag
43 Intensive Blood Pressure Intervention in Stroke (IBIS) Trial Not yet recruiting NCT03585595 Phase 3
44 Benefit of Controlled Rehydration in Unexplained Syncope Terminated NCT00143754 Phase 3
45 BRD 06/2-D (Quidam) "Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator" Terminated NCT00927732 Phase 3 hydroquinidine;placebo (sugar)
46 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL Withdrawn NCT01560091 Phase 3 silodosin;Tamsulosin
47 Acarbose and Older Adults With Postprandial Hypotension Unknown status NCT01914133 Phase 2 Acarbose;Placebo
48 ECG Device for Long QT Syndrome Screening in Newborns Unknown status NCT02412709 Phase 2
49 A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST6 Completed NCT02500732 Phase 2 Atomoxetine;Placebo
50 A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope (POST 6) Completed NCT02874937 Phase 2 Atomoxetine;Matching Placebo

Search NIH Clinical Center for Syncope

Genetic Tests for Syncope

Genetic tests related to Syncope:

# Genetic test Affiliating Genes
1 Syncope 29

Anatomical Context for Syncope

MalaCards organs/tissues related to Syncope:

40
Testes, Heart, Brain, Skin, Lung, Prostate, Spinal Cord

Publications for Syncope

Articles related to Syncope:

(show top 50) (show all 15839)
# Title Authors PMID Year
1
Incidence and predictors of atrial fibrillation in a Chinese cohort of Brugada syndrome. 61
32387420 2020
2
The exudative-constrictive tuberculosis pericarditis diagnosed by toracoscopic biopsy. 61
32462083 2020
3
High rate of re-bleeding after application of Hemospray for upper and lower gastrointestinal bleeds. 61
32127325 2020
4
Right ventricular strain in patients with pulmonary embolism and syncope. 61
31667788 2020
5
Vestibular drop attacks in Ménière's disease and its association with migraine. 61
32185501 2020
6
Sudden Cardiac Death in Brugada Syndrome. 61
31008774 2020
7
Pediatric-Onset Postural Orthostatic Tachycardia Syndrome in a Single Tertiary Care Center. 61
32314650 2020
8
First transcatheter leadless pacemaker implantation in a pediatric patient with a genetic disease. 61
32372230 2020
9
[Cardiac Tamponade by Chest Compression at Cardiopulmonary Resuscitation;Report of a Case]. 61
32475968 2020
10
Endovascular Management of Intracranial Vertebral Artery Dissection: Technical Nuances for the Preservation of Posterior Inferior Cerebellar Artery and Basilar Artery. 61
32526018 2020
11
Venous Pooling in Suspension Syndrome Assessed with Ultrasound. 61
31843349 2020
12
Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany. 61
32003157 2020
13
Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. 61
32445688 2020
14
The incidence of first seizures, epilepsy and seizure mimics in a geographically defined area. 61
32518150 2020
15
From Other Journals: A Review of Recent Articles in Pediatric Cardiology. 61
32572547 2020
16
[Severe noncardiogenic pulmonary edema due to permeability disorder after i.v. administration of CT contrast medium with subsequent venovenous extracorporeal membrane oxygenation]. 61
32548721 2020
17
Ivabradine in children with postural orthostatic tachycardia syndrome: a retrospective study. 61
32498748 2020
18
Pediatric Syncope: A Systematic Review. 61
32530839 2020
19
Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease. 61
32565346 2020
20
Isolated Exercise-Induced Pulmonary Hypertension Associates with Higher Cardiovascular Risk in Scleroderma Patients. 61
32570917 2020
21
MOdified DIagnostic strateGy to safely ruLe-out pulmonary embolism In the emergency depArtment: study protocol for the Non-Inferiority MODIGLIANI cluster cross-over randomized trial. 61
32493383 2020
22
Predicting sudden cardiac death in adults with congenital heart disease. 61
32546506 2020
23
Performance of the entirely subcutaneous ICD in borderline indications. 61
31586219 2020
24
[Syncope]. 61
32542492 2020
25
Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. 61
32299753 2020
26
Helium inhalation injuries managed at emergency departments. 61
32527163 2020
27
Syncope and Alternating QRS Morphology. 61
32479204 2020
28
Bradycardia and syncope: the case of the torted gallbladder. 61
32574427 2020
29
Giant pericardial cyst as the cause of syncope. 61
32533156 2020
30
Todd's paresis following vasovagal syncope provoked by tilt-table testing. 61
32513764 2020
31
An analysis of vascular properties using pulse wave analysis in patients with vasovagal syncope. 61
32557670 2020
32
The importance of dedicated teams for the management of patients with syncope. 61
32532537 2020
33
[Superior Vena Cava Syndrome]. 61
32541158 2020
34
Assessment of conduction anesthesia effectiveness using the angulated needle approach for the inferior alveolar nerve block. 61
32340906 2020
35
Loop Recorder Implantation on a Telemetry Ward. 61
32307087 2020
36
Heat Policy Revision for Georgia High School Football Practices Based on Data-Driven Research. 61
32559286 2020
37
Validation of a new risk score system for non-variceal upper gastrointestinal bleeding. 61
32552662 2020
38
Contemporary management of patients with syncope in clinical practice: an EHRA physician-based survey. 61
32449760 2020
39
Letter by Sutton et al Regarding Article, "Abolish the Tilt Table Test for the Workup of Syncope!" 61
32568588 2020
40
EGSYS score for the prediction of cardiac etiology in syncope: Is it useful in an outpatient setting? 61
32534800 2020
41
Pathophysiology and Individualized Management of Vasovagal Syncope and Postural Tachycardia Syndrome in Children and Adolescents: An Update. 61
32367250 2020
42
Response by Levine and Mody to Letter Regarding Article, "Abolish the Tilt Table Test for the Workup of Syncope!" 61
32568585 2020
43
Validation and Disease Risk Assessment of Previously Reported Genome-Wide Genetic Variants Associated with Brugada Syndrome: SADS-TW BrS Registry. 61
32490690 2020
44
Lipoprotein(a): Expanding our knowledge of aortic valve narrowing. 61
32525013 2020
45
Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study. 61
32532845 2020
46
A Young Patient Presenting with Atrioventricular Block Diagnosed as Myotonic Dystrophy. 61
32188809 2020
47
Plasma adenosine and neurally mediated syncope: ready for clinical use. 61
32449908 2020
48
Chronic thromboembolic pulmonary hypertension secondary to implantable cardioverter defibrillator lead thrombus in a patient with Brugada syndrome: a rare complication requiring a multidisciplinary approach. 61
32434878 2020
49
Proarrhythmic effects from competitive atrial pacing and potential programming solutions. 61
32452039 2020
50
Life-threatening cardiac arrhythmias in congenital central hypoventilation syndrome. 61
31950261 2020

Variations for Syncope

ClinVar genetic disease variations for Syncope:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ACTL6A NM_004301.5(ACTL6A):c.1129C>T (p.Arg377Trp)SNV Likely pathogenic 549661 rs868064163 3:179304340-179304340 3:179586552-179586552
2 SCN5A NM_001099404.1(SCN5A):c.1255C>T (p.Gln419Ter)SNV Likely pathogenic 374130 rs1057518916 3:38647525-38647525 3:38606034-38606034
3 MEFV NM_000243.3(MEFV):c.2084A>G (p.Lys695Arg)SNV Conflicting interpretations of pathogenicity 2547 rs104895094 16:3293403-3293403 16:3243403-3243403
4 KCNE3 , LIPT2 NM_005472.4(KCNE3):c.248G>A (p.Arg83His)SNV Conflicting interpretations of pathogenicity 5541 rs17215437 11:74168361-74168361 11:74457316-74457316
5 TTN NM_001267550.2(TTN):c.11311+4088A>GSNV Conflicting interpretations of pathogenicity 47753 rs142304137 2:179613763-179613763 2:178749036-178749036
6 ACTN2 NM_001103.3(ACTN2):c.1040C>T (p.Thr347Met)SNV Conflicting interpretations of pathogenicity 178985 rs727504590 1:236902765-236902765 1:236739465-236739465
7 RYR2 NM_001035.3(RYR2):c.2026G>A (p.Glu676Lys)SNV Uncertain significance 689574 1:237659875-237659875 1:237496575-237496575
8 DSP NM_004415.4(DSP):c.1388T>C (p.Leu463Pro)SNV Uncertain significance 870076 6:7568791-7568791 6:7568558-7568558

Expression for Syncope

Search GEO for disease gene expression data for Syncope.

Pathways for Syncope

Pathways related to Syncope according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.05 TNNT2 SCN5A RYR2 NPPA KCNQ1
2
Show member pathways
11.95 TTN TNNT2 SCN5A RYR2 NPPA KCNQ1
3
Show member pathways
11.88 TTN TNNT2 RYR2
4 11.77 SCN5A RYR2 KCNQ1 KCNH2
5 11.36 TTN TNNT2 ACTN2
6
Show member pathways
11.09 SLC6A2 DBH
7 11 SCN5A RYR2 KCNQ1 KCNH2
8 10.77 SLC6A2 DBH
9
Show member pathways
10.73 SLC6A2 DBH

GO Terms for Syncope

Cellular components related to Syncope according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.26 TTN SCN5A RYR2 ACTN2
2 striated muscle thin filament GO:0005865 9.16 TTN TNNT2
3 sarcomere GO:0030017 8.92 TTN TNNT2 RYR2 ACTN2

Biological processes related to Syncope according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.94 SCN5A RYR2 KCNQ1 KCNH2
2 transmembrane transport GO:0055085 9.88 SLC6A2 SCN5A RYR2 KCNQ1 KCNH2
3 regulation of ion transmembrane transport GO:0034765 9.8 SCN5A KCNQ1 KCNH2
4 muscle contraction GO:0006936 9.76 TTN TNNT2 ACTN2
5 regulation of heart contraction GO:0008016 9.64 TNNT2 KCNQ1
6 regulation of heart rate GO:0002027 9.63 SCN5A RYR2
7 cardiac conduction GO:0061337 9.63 SCN5A KCNQ1 KCNH2
8 response to pain GO:0048265 9.62 SLC6A2 DBH
9 membrane depolarization during action potential GO:0086010 9.62 SCN5A KCNH2
10 response to muscle stretch GO:0035994 9.61 RYR2 NPPA
11 positive regulation of potassium ion transmembrane transport GO:1901381 9.61 KCNQ1 KCNH2
12 sarcomere organization GO:0045214 9.61 TTN TNNT2 ACTN2
13 potassium ion export across plasma membrane GO:0097623 9.6 KCNQ1 KCNH2
14 cellular response to epinephrine stimulus GO:0071872 9.59 RYR2 KCNQ1
15 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.58 KCNQ1 KCNH2
16 regulation of heart rate by cardiac conduction GO:0086091 9.58 SCN5A KCNQ1 KCNH2
17 membrane repolarization GO:0086009 9.57 KCNQ1 KCNH2
18 positive regulation of cardiac muscle contraction GO:0060452 9.56 NPPA KCNQ1
19 regulation of membrane repolarization GO:0060306 9.55 KCNQ1 KCNH2
20 cardiac muscle hypertrophy GO:0003300 9.54 TTN RYR2
21 muscle filament sliding GO:0030049 9.54 TTN TNNT2 ACTN2
22 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.52 KCNQ1 KCNH2
23 atrial cardiac muscle cell action potential GO:0086014 9.51 SCN5A KCNQ1
24 positive regulation of heart rate GO:0010460 9.5 RYR2 NPPA KCNQ1
25 membrane repolarization during action potential GO:0086011 9.49 KCNQ1 KCNH2
26 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.43 SCN5A KCNQ1 KCNH2
27 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.33 SCN5A NPPA KCNQ1
28 ventricular cardiac muscle cell action potential GO:0086005 9.26 SCN5A RYR2 KCNQ1 KCNH2
29 cardiac muscle contraction GO:0060048 9.1 TTN TNNT2 SCN5A RYR2 KCNQ1 KCNH2

Molecular functions related to Syncope according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.81 TTN TNNT2 RYR2 ACTN2
2 voltage-gated ion channel activity GO:0005244 9.61 SCN5A KCNQ1 KCNH2
3 structural constituent of muscle GO:0008307 9.49 TTN ACTN2
4 delayed rectifier potassium channel activity GO:0005251 9.48 KCNQ1 KCNH2
5 protein kinase A regulatory subunit binding GO:0034237 9.46 RYR2 KCNQ1
6 calmodulin binding GO:0005516 9.46 TTN SCN5A RYR2 KCNQ1
7 scaffold protein binding GO:0097110 9.43 SCN5A KCNQ1 KCNH2
8 protein kinase A catalytic subunit binding GO:0034236 9.4 RYR2 KCNQ1
9 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.37 KCNQ1 KCNH2
10 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.32 KCNQ1 KCNH2
11 ion channel activity GO:0005216 9.26 SCN5A RYR2 KCNQ1 KCNH2
12 ion channel binding GO:0044325 8.92 SCN5A RYR2 KCNQ1 ACTN2

Sources for Syncope

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....